Inivata’s Nitzan Rosenfeld to Receive 2020 Cancer Researcher Award from the European Association for Cancer Research and Pezcoller Foundation

Research Triangle Park, NC, USA and Cambridge, UK, February 27, 2020 – Inivata, a leader in liquid biopsy, is pleased to announce that Dr. Nitzan Rosenfeld, Co-founder and Chief Scientific Officer at Inivata has been announced the winner of the 2020 Pezcoller Foundation European Association for Cancer Research (EACR) Cancer Researcher Award.

Nitzan Rosenfeld is a globally recognized expert in liquid biopsy and translational cancer research. He co-founded Inivata in 2014, and has continued to play a key role in ensuring that the company remains at the forefront of the clinical implementation of liquid biopsy. Dr. Rosenfeld also leads the Liquid Biopsies and Cancer Diagnostics academic research group at the CRUK Cambridge Institute, University of Cambridge. This group is focused on innovation in methods for analysis of circulating tumor DNA and is a pioneer in novel liquid biopsy approaches.

The Pezcoller Foundation EACR Cancer Researcher Award celebrates academic excellence and achievements in the field of cancer research and will be presented at the annual EACR 2020 Congress in Torino, Italy on 17-20 June 2020. Dr. Rosenfeld will also deliver the award lecture at the congress.

Dr. Nitzan Rosenfeld, Co-founder and Chief Scientific Officer at Inivata, commented:
“It is an honor to receive this prestigious award from an institution whose members are dedicated to conducting such important research in the fight against cancer. Liquid biopsy has the potential to transform the lives of cancer patients and their families. The recognition for having made a contribution to this field is a great encouragement, and I hope it will help inspire further research and future researchers.”

About Inivata
Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

About the European Association for Cancer Research
The European Association for Cancer Research is a global community of cancer researchers with more than 10,000 members in 100+ countries. EACR membership is open to anyone working in or studying cancer research and members work across the full spectrum of the field, from basic through to translational and clinical research. EACR members range from PhD students to winners of the Nobel Prize.

The EACR’s mission is ‘The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.’ They facilitate communication and collaboration within the cancer research community, provide a wide variety of services to their community of members, and organise scientific conferences of the highest quality. They also set out to raise the profile of cancer research in Europe and to make the case for sustained political and economic support.

About the Pezcoller Foundation
The Pezcoller Foundation is a non-profit institution, whose goal is to promote scientific research against diseases which afflict mankind, specifically the fight against cancer. The Founder, Prof. Alessio Pezcoller, was Chief Surgeon at Santa Chiara Hospital in Trento, Italy. The Foundation was established in 1980.

The Foundation depends primarily on the substantial sum of money bequeathed by Professor Alessio Pezcoller, and by significant contributions from its sponsors: the Cassa di Risparmio di Trento e Rovereto Foundation, the Province of Trento, the Administrative Councils of Trento and of Rovereto and other occasional private donations.

Due to its ever-increasing recognition within the international oncological community, the Foundation collaborates with some of the most important cancer institutions: the American Association for Cancer Research (AACR) and the European Association for Cancer Research (EACR). The Pezcoller Awards are officially recognized during the international conferences of the two above mentioned associations.

 

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US)

inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271

 

Karen Chandler-Smith

karen.chandler-smith@inivata.com +44 (0)7900 430235

 

Our Technology

Our Solutions

Latest News